CRISPR Therapeutics AG Accounts Payable for the year ending December 31, 2024: USD 14.71 M

CRISPR Therapeutics AG Accounts Payable is USD 14.71 M for the year ending December 31, 2024, a -61.44% change year over year. Accounts payable are amounts owed by the company to suppliers or vendors for goods or services received but not yet paid.
  • CRISPR Therapeutics AG Accounts Payable for the year ending December 31, 2023 was USD 38.15 M, a 39.08% change year over year.
  • CRISPR Therapeutics AG Accounts Payable for the year ending December 31, 2022 was USD 27.43 M, a 85.12% change year over year.
  • CRISPR Therapeutics AG Accounts Payable for the year ending December 31, 2021 was USD 14.82 M, a 62.92% change year over year.
  • CRISPR Therapeutics AG Accounts Payable for the year ending December 31, 2020 was USD 9.09 M, a 52.99% change year over year.
Key Data
Date Accounts Payable Short-Term Debt Long-Term Debt Total Liabilities